Park City, UT

3 days / 6 sessions
Current Issues in Spine

February 2-4, 2017

juvent-health-451.jpg

June 8, 2017 OrthoSpineNews

RIVIERA BEACH, FL–(Marketwired – June 07, 2017) – Juvent (www.juvent.com) a leader in orthopaedic regenerative therapies for bone and musculoskeletal health announced today the engagement of Scott D. Boden, MD as Chief Medical Advisor. Dr. Boden is a tenured Professor of Orthopaedic Surgery at the Emory University School of Medicine and serves as the Director of the Emory Orthopeadics & Spine Center, Vice Chair of Orthopaedics, CMO/CQO of The Emory University Orthopaedics & Spine Hospital, and Emory Healthcare Physician Director of Strategy and Development for Orthopaedics & Spine Programs.

Dr. Boden has received numerous awards for his work and is the author of more than 175 peer-reviewed articles on spine and basic science topics; as well as 30 chapters and seven textbooks. He is co-editor of Seminars in Spine Surgery, a deputy editor of SPINE, and a reviewer for the Journal of Bone and Joint Surgery, the Journal of Bone and Mineral Research, and the European Spine Journal.

“Dr. Boden brings in-depth experience and perspective to our group and has a unique blend of medicine, science, and business skills,” said Rush Simonson, Chairman & CEO of Regenerative Technologies Corporation. “His reputation and expertise will help us in our quest to expand the clinical value of the Juvent technology.”

In 2013, Dr. Boden served as President of the American Orthopaedic Association. He received his B.A. and M.D. from the University of Pennsylvania and completed an Orthopaedic Residency at The George Washington University Medical Center, followed by a Spine Fellowship at Case Western Reserve University Hospitals.

Additionally, Dr. Boden, Emory Orthopaedics and Spine are also pioneering a sports team and academic health-care partnership with the Atlanta Hawks and P3 (Peak Performance Project) in a soon to open 90,000-square foot, $50 million-dollar facility. Juvent is playing an ever-increasing role in professional sports as their device helps to rehab athletes and speed recovery time after training. Olympic gold medal tennis champion, Mike Bryan, uses Juvent daily as well as many other national football players, such as Eric Wood, Center with the Buffalo Bills.

Juvent’s presence in physical therapy centers continues to grow with one leading therapy franchise putting over 80% of their patients on Juvent at each visit. “Dr. Boden’s experience and expertise in bone health is widely recognized and he will help drive Juvent’s product development and clinical applications,” said Juvent President, Peter Simonson.

“We are just before entering our next round of funding to complete development and production of a low-cost consumer unit to meet the demand of a broader consumer market. Over 50 million people who suffer from osteoarthritis in the U.S. could benefit from this safe, non-invasive technology,” said Chairman & CEO Rush Simonson.

Juvent’s Micro-Impact Platform® is registered as a FDA Class I medical exercise and rehabilitation device. Juvent uses a unique, patented resonant wave technology to deliver thousands of low-magnitude and high-frequency micro-impacts that enter through the heels of the feet and move up the entire body. These micro-impacts safely stimulate the body’s muscles and bones to rebuild. Users stand on the Juvent for as little as 10 minutes per day and many begin to feel joint pain relief within days. Juvent’s platform is recommended and used by world-renowned trainers, doctors, physical therapists, and chiropractors. Juvent holds over 26 patents worldwide on its technology.

Juvent’s platform is also used in the athletic world for recovery and healing by leading organizations such as The David Leadbetter Golf Academy, NFL Alumni Association (NFLA), and Hospital for Special Surgery’s, Pete Draovitch, PT, MS, ATC, CSCS. Some of the champion athletes using Juvent in their daily training regimens include; Olympic Tennis Champion Mike Bryan, former NFL legend, Ray Lewis, Eric Wood, with the Buffalo Bills and tennis legend Mats Wilander.

Juvent is a Corporate Advisory Roundtable Member of the National Osteoporosis Foundation (NOF).

About Juvent:

Juvent is a part of Regenerative Technologies Corporation, a privately held, Florida based company who manufactures the Juvent Micro-Impact Platform® here in the U.S. The platform provides non-invasive, micro-impact pulses to support bone health, lymphatic drainage, relieve joint and back pain, and enhance balance. The Class I medical exercise and rehabilitation device is the result of more than 20 years and $45 million in R&D, with many peer-reviewed journals articles and 6 human clinical studies (completed or current) with backing from the National Institutes of Health (NIH), NASA, and the U.S. Army. Used by world-renowned medical doctors, trainers, physical therapists, and chiropractors, for more information, visit www.juvent.com or follow us on Twitter @JuventHealth, Facebook Juvent Health and, Facebook Juvent Sports

In the U.S., the Juvent 1000N device is considered investigational for the treatment of osteoporosis or improvement/maintenance of bone mineral density (BMD).

Image Available: http://www.marketwire.com/library/MwGo/2017/6/6/11G140561/Images/Scott_D._Boden,_MD_2017-629ecab0215885c7bb1a88ab05d2c83d.jpg

CONTACT INFORMATION



June 8, 2017 OrthoSpineNews

June 07, 2017

DURHAM, N.C.–(BUSINESS WIRE)–Bioventus, a global leader in orthobiologics, today announced that, effective June 1, 2017, its full surgical orthobiologics portfolio is available through Premier, Inc. Premier is a health care improvement company comprised of 3,750 US hospitals and more than 130,000 other provider organizations throughout the country. Bioventus Surgical has numerous offerings for bone healing and spine fusion including allograft bone, synthetic bone graft substitutes and cell and marrow extraction needles.

OSTEOAMP®, an allograft fusion solution, has been available through Premier since 2012. Additional products in the new agreement include: SIGNAFUSE, a bioactive bone graft substitute, EXPONENT demineralized bone matrix, PUREBONE® demineralized cancellous bone and cancellous chips, INTERFACE bioactive bone graft, OSTEOMATRIX® biphasic mineral/collagen bone graft, OSTEOPLUS® biphasic mineral bone graft, CELLXTRACT®, an autologous cell and marrow extraction device, and EXTRACTOR autologous cell and marrow extraction device.

“The Bioventus Surgical portfolio is designed to meet the needs of surgeons and their patients, across a broad range of clinical situations, procedures, and costs,” said Henry Tung, MD, Senior Vice President, Bioventus and President, Bioventus Surgical. “We expect the Premier alliance of hospitals and healthcare providers to benefit greatly from our clinically supported and cost-effective orthobiologic solutions.”

About Bioventus

Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The company has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical that make it a global leader in active orthopaedic healing. Its EXOGEN® Ultrasound Bone Healing System uses safe, effective low intensity pulsed ultrasound (LIPUS) to stimulate the body’s natural healing process. EXOGEN has been used to treat more than 1 million patients worldwide and numerous regulatory agencies including the FDA, Health Canada, BSi, TGA, Medsafe, UAE Ministry of Health and SFDA have granted their approval of the product. Today it is the leading bone healing system in the market with complaints for lack of efficacy averaging less than 1%.

Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.BioventusGlobal.com and follow the company on Twitter @Bioventusglobal.

Bioventus, the Bioventus logo, CELLXTRACT, OSTEOAMP, OSTEOMATRIX, OSTEOPLUS, PUREBONE and EXOGEN are registered trademarks, and EXPONENT, EXTRACTOR and SIGNAFUSE are trademarks of Bioventus LLC.

Summary of Indications for Use

Please see Instructions for Use for complete lists of indications, contraindications, warnings, and precautions on the product labels, at www.BioventusSurgical.com, or by calling 1-800-637-4391.

CELLXTRACT is intended for use for aspiration of bone marrow or autologous blood using a standard piston syringe.

EXPONENT Demineralized Bone Matrix is indicated for bony voids or gaps that are not intrinsic to the stability of the bony structure. It is intended to be gently packed into bony voids or gaps of the skeletal system (posterolateral spine). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone.

EXTRACTOR is intended for the purpose of harvesting bone marrow.

INTERFACE Bone Void Filler is indicated for bony voids or gaps that are not intrinsic to the stability of bony structures. These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. INTERFACE Bone Void Filler is indicated to be gently packed into bony voids or gaps of the skeletal system (extremities and pelvis), and in the posterolateral spine when mixed with autograft. The product provides a bone void filler that resorbs and is replaced with bone during the healing process.

OSTEOAMP may be used in situations where an autograft is appropriate. It should be restricted to homologous use for the repair, replacement or reconstruction of musculoskeletal defects.

OSTEOMATRIX is indicated for use in bony voids or gaps that are not intrinsic to the stability of the bony structure. The product should be gently packed into bony voids or gaps of the skeletal system (i.e., the extremities, posterolateral spine and pelvis). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone.

OSTEOPLUS is intended for use as a bone void filler for bony voids or gaps of the skeletal system (e.g., extremities, spine and pelvis) that are not intrinsic to the stability of the bony structure. OSTEOPLUS can be used with autograft as a bone graft extender. These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone.

PUREBONE Demineralized Cancellous Tissue is restricted to use by a licensed physician. PUREBONE Demineralized Cancellous Tissue can be used in orthopedic, neurosurgical and reconstructive bone grafting procedures for homologous use for the repair, replacement, or reconstruction of musculoskeletal defects. It can be used by itself as a bone graft or in conjunction with autologous bone and other forms of allograft bone. PUREBONE Demineralized Cancellous Tissue has been tested for sterility and is ready for use. Do not subject the product to additional disinfection or sterilization procedures. PUREBONE Demineralized Cancellous Tissue is intended for single patient use only. In order to prevent contamination of the graft, any open and unused PUREBONE Demineralized Cancellous Tissue must be discarded and not used in other patients.

SIGNAFUSE is a bone void filler device intended for use in bony voids or gaps that are not intrinsic to the stability of bony structure. These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. SIGNAFUSE is indicated to be packed gently into bony voids or gaps of the skeletal system (i.e., extremities, pelvis and posterolateral spine fusion procedures). SIGNAFUSE can also be used with autograft as a bone graft extender in the posterolateral spine. The device provides a bone void filler that is resorbed and replaced with host bone during the healing process.

Contacts

Bioventus LLC
Thomas Hill, 919-474-6715
thomas.hill@bioventusglobal.com


AAEAAQAAAAAAAAUAAAAAJDMwZmQ0NGEzLWE2Y2ItNGU4My1hYmYzLTQ2YmMyODBjMjQ4OQ.png

June 8, 2017 OrthoSpineNews

June 07, 2017

SAN DIEGO–(BUSINESS WIRE)–Active Implants, a company that develops orthopedic implant solutions, today announced that the company’s SUN (Safety Using NUsurface®) trial is now underway in San Diego. Dr. Scott A. Hacker at Grossmont Orthopaedic Medical Group is the only physician in San Diego County – and the center is one of just 10 sites nationwide – participating in the SUN clinical trial to evaluate the investigational NUsurface Meniscus Implant (pronounced “new surface”) for the treatment of persistent knee pain caused by injured or deteriorating meniscus cartilage.

The meniscus is a tissue pad between the thigh and shin bones. Once damaged, the meniscus has a very limited ability to heal. Over 1 million partial meniscectomies to remove or repair a torn meniscus are performed in the U.S. every year, about the same as the total number of hip and knee replacement surgeries combined. However, many patients still experience persistent knee pain following meniscus surgery.

“Current treatments for meniscus-related chronic knee pain do not address the underlying biology of the knee pain,” Dr. Hacker said. “Injections and medications do provide temporary relief for some patients but are just masking the symptoms. We hope this study finds that the NUsurface implant addresses the underlying problem and gets rid of the discomfort, allowing patients to return to the leisure and work activities that had been hindered by pain.”

The SUN study will enroll approximately 120 patients as part of regulatory process to gain approval from FDA to sell the device in the U.S. All patients who meet study requirements and agree to enter the trial are offered the NUsurface Meniscus Implant as treatment. Treatment with NUsurface in the SUN trial is eligible for coverage by Medicare and some private insurance companies. To be eligible for the study, participants must be between the ages of 30 and 75 and have pain after medial meniscus surgery that was performed at least six months ago. To learn more about the SUN study, please visit http://sun-trial.com or call (844) 680-8951.

About the NUsurface® Meniscus Implant

The NUsurface® Meniscus Implant is an investigational treatment for patients with persistent knee pain following medial meniscus surgery. It is made from medical grade plastic and, as a result of its unique materials, composite structure and design, does not require fixation to bone or soft tissues. The NUsurface Meniscus Implant mimics the function of the natural meniscus and redistributes loads transmitted across the knee joint. Clinical trials are underway in the U.S., Europe and Israel to verify the safety and effectiveness of the NUsurface Meniscus Implant.

About Active Implants

Active Implants, LLC develops orthopedic implant solutions that complement the natural biomechanics of the musculoskeletal system, allowing patients to maintain or return to an active lifestyle. Active Implants is privately held with headquarters in Memphis, Tennessee. European offices are in Driebergen, The Netherlands, with R&D facilities in Netanya, Israel. For more information, visit www.activeimplants.com.

CAUTION Investigational device. Limited by United States law to investigational use.

Contacts

Merryman Communications
Joni Ramirez, 323-532-0746
joni@merrymancommunications.com


oska_0-1.jpg

June 7, 2017 OrthoSpineNews

CARLSBAD, CA, June 7, 2017 – Oska Wellness, a technology company committed to developing consumer health and wellness products, announced that its Oska Pulse has been selected as the “Best IoT Healthcare Wearable Device” award winner from MedTech Breakthrough, an independent organization that recognizes the top companies, technologies and products in the global health and medical technology market.

“All of us at Oska are excited to receive this award from MedTech, who have recognized Oska’s mission to provide non-invasive, drug-free pain management solutions,” said Greg Houlgate, Oska Wellness CEO. “This is an important industry recognition for our year-old company and our flagship device, Oska Pulse. We’re very grateful.”

The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories, including Patient Engagement, Electronic Health Records (HER), mHealth, Medical Devices, Medical Data and many more. This year’s program attracted more than 2,000 nominations from more than 10 countries. All nominations were evaluated by an independent panel of experts within the medical and health industry, including media, analysts, and technology executives.

“We are thrilled to recognize Oska Wellness with this well-deserved industry recognition for innovation in the health and medical technology field,” said James Johnson, managing director, MedTech Breakthrough. “For the millions of Americans that suffer from chronic pain, Oska Pulse is a compelling solution and the MedTech Breakthrough Award designation is a testament to the skill, ingenuity, and vision of the Oska Wellness team.”

Oska Pulse is a safe, easy-to-use, portable and wearable health technology product designed to help reduce muscle stiffness, temporarily relieve minor pain and increase mobility for people who have acute or chronic pain.

About Oska Wellness 
Oska, Inc. is committed to developing health and wellness technology-driven products that assist individuals in living a more active, pain-free lifestyle. Oska Pulse utilizes patented eTec Pulse Technology that specifically optimizes Pulsed Electromagnetic Field (PEMF) therapeutic technology, similar to the PEMF therapies used in many clinical applications for accelerating the body’s ability to heal itself.

The science and technology behind Oska Pulse was engineered and developed by a team of respected scientists and researchers with more than 25 years of experience in engineering health and wellness technologies to treat pain. Oska Wellness, Inc. does not claim the product to diagnose, treat, cure or prevent any medical condition. The company is headquartered in Carlsbad, California and can be found online at www.oksawellness.com.

About MedTech Breakthrough
The MedTech Breakthrough Awards program is devoted to honoring excellence in medical and health related technology companies, products and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough MedTech companies and products in categories including Patient Engagement, mHealth, Health & Fitness, Clinical Administration, Healthcare IoT, Genomics, Medical Data, Healthcare Cybersecurity and more. For more information visit www.MedTechBreakthrough.com

 

ADD COUPON CODE  “ORTHOSPINECO”  FOR  $55.00 OFF

READ MORE ABOUT OSKA HERE

 

 

 

 

 


img_product_egps-1.jpg

June 6, 2017 OrthoSpineNews

June 06, 2017

GAINESVILLE, Fla.–(BUSINESS WIRE)–Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products and biologic solutions for extremities, knee and hip, announced today a successful first surgery using the new Equinoxe® Preserve stem, a conservative shoulder treatment option designed to preserve humeral bone in shoulder replacement surgery. Additionally, surgeons performed the first U.S. procedures using the ExactechGPS® Shoulder Application.

Orthopaedic surgeon Thomas Wright, MD, performed the first Preserve stem surgery in Gainesville, Fla. “The surgical team and I were pleased with the results of today’s surgery, including the thoughtful implant design, practical instrumentation and relatively simple technique,” Dr. Wright said.

The Preserve stem expands the options offered by the successful Equinoxe®Platform Shoulder System. This new stem is approximately two-thirds the length of the system’s current stem.

“Creating a bone preserving stem that can be used alongside already clinically successful components of our Equinoxe anatomic and reverse implants is an important evolutionary step in our perpetual pursuit of improved clinical outcomes,” said Darin Johnson, Vice President of Marketing, Extremities.

The implant design was developed through the use of CT reconstruction data and clinical studies. Specifically, the implant features a unique polished distal tip to facilitate any need for removal, a straight lateral fin designed for greater rotational stability and plasma coating to aid proximal fixation.

“The technique and implant were created to provide a more bone preserving option within the Equinoxe suite. It was a great pleasure over the last couple of years to collaborate with Drs. Samuel Antuna, Ken Faber, Howard Routman, Joseph Zuckerman and Pierre-Henri Flurin on this innovative improvement. This product demonstrates Exactech’s commitment to working closely with surgeons to improve patient outcomes,” Dr. Wright said.

Dr. Wright and Richard Jones, MD, of Asheville, N.C., also completed the first U.S. surgeries using the ExactechGPS Shoulder Application, a computer-assisted shoulder arthroplasty technology. “This advance in shoulder arthroplasty – being able to execute a preoperative plan in the operating room with real-time visibility into the glenoid vault – has almost limitless possibilities to help patients. Ten years ago, Dr. Sean Grey and I implanted the first Equinoxe reverse shoulder, and that innovation set the pace for the last decade. Now, I believe, ExactechGPS is the breakthrough for the next decade,” Dr. Jones said.

Full U.S. market availability for the Preserve Stem and ExactechGPS Shoulder Application is planned for the beginning of 2018.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at http://www.exac.com.

A current investment profile on Exactech (Nasdaq: EXAC) is available online at http://www.hawkassociates.com/profile/exac.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.

Contacts

Exactech
Investor contacts:
Jody Phillips, 352-377-1140
Executive Vice President of Finance & Chief Financial Officer
or
Hawk Associates
Julie Marshall or Frank Hawkins, 305-451-1888
EXAC@hawkassociates.com
or
Exactech
Media contact:
Priscilla Bennett, 352-377-1140
Vice President, Corporate & Marketing Communication


BIO-1.jpg

June 6, 2017 OrthoSpineNews

June 06, 2017

HUNTLEY, Ill.–(BUSINESS WIRE)–Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today exponential growth of their Biologics product line, OSTEO-LINK™ Demineralized Bone Matrix, over the past fiscal year.

“OSTEO-LINK has been engineered and processed to deliver the highest level of osteoinductivity. It is because of this technology that we have achieved record breaking revenue growth of 424% over the past year,” said Mariusz Knap, Vice President of Marketing for Life Spine. “From April to May alone, we experienced a 270% revenue jump. This has been possible through our many differentiated offerings of putty, strips, cubes and fillers all available to help influence better patient outcomes and reduce costs.”

Life Spine expects continued growth of their Biologics line with the announcement of two new Biologic offerings. First, OSTEO-LINK Hydratable ICM (Inductive Carrier Matrix), which is an osteoinductive bone matrix that may be hydrated with saline, blood, BMA, or PRP. OSTEO-LINK Hydratable ICM does not contain any extrinsic carriers and is made from 100% human bone. The graft also has exceptional handling characteristics that resists irrigation. All OSTEO-LINK products are verified for osteoinductivity post-sterilization prior to release for distribution. In-vivo test results demonstrate all 5 bone forming elements present (chondrocytes, osteocytes, bone marrow cells, cartilage, and new bone).

Second, the patent pending MARROW CELLUTION™ Bone Marrow Harvesting System, designed to overcome the limitations of a traditional bone marrow needle and results in a bone marrow harvest that is so rich in key stem and progenitor cells that the aspirate may no longer require manipulation through centrifugation prior to application. Traditional needles produce excess peripheral blood contamination, diminishing cellular yield; thereby requiring additional manipulation steps to achieve the cellular demand necessary for most clinical indications. MARROW CELLUTION uses its patent(s) pending technology to harvest high quality stem and progenitor cells from various levels within the marrow space, while limiting peripheral blood contamination.

About Life Spine

Life Spine is dedicated to improving the quality of life for spinal patients by increasing procedural efficiency and efficacy through innovative design, uncompromising quality standards, and the most technologically advanced manufacturing platforms. Life Spine, which is privately held, is based in Huntley, Illinois. For more information, please visit: http://www.lifespine.com.

Contacts

Life Spine
Mr. Omar Faruqi
Chief Financial Officer
ofaruqi@lifespine.com
847-884-6117


oska-pulse-render-R34-700x600_1024x1024-1.jpg

June 6, 2017 OrthoSpineNews

CARLSBAD, Calif., May 31, 2017 /PRNewswire/ — Oska Wellness, a technology company committed to developing innovative consumer health and wellness products, is partnering with the Arizona Golf Association to promote Oska Pulse, a breakthrough wearable electromagnetic field device that eases pain.  The AGA is comprised of more than 400 clubs and 75,000 members.

“I used Oska Pulse both prior to and after my hip surgery last year,” said Ed Gowan, Executive Director of the AGA.  “We’re always interested in bringing new products and options to Arizona Golf members. If they can use Oska Pulse to play one more round, then we’re all for recommending it to our community.”

Oska Pulse is a safe, easy-to-use, wearable health technology product designed to help reduce muscle stiffness, temporarily relieve minor pain and increase mobility for people who have acute or chronic pain.

“I met Ed Gowan in 2010 while in the golf industry and am delighted to forge an official relationship with the Arizona Golf Association,” said Steve Collins, COO of Oska Wellness. “The AGA shares our mission for new ways to provide non-invasive, drug-free pain management solutions. Many golfers have told us that they’ve had to cut back on playing due to elbow, hip, wrist, knee, back pain and more. Those who have used Oska Pulse now view the device as just as important to managing their aches and pains as a putter or a driver is to his or her game.”

The Arizona Golf Association was founded in 1923 as a small group of golfers who got together to run the annual Amateur Championship.  The AGA is a volunteer-based organization directed by amateur golfers, dedicated to promoting the game of golf, and providing valuable benefits and services to its members.

During the PGA Merchandise Show in January, Oska Wellness introduced Oska Pulse, a hands-free device that employs safe Pulsed Electromagnetic Field (PEMF) therapeutic technology to help people enjoy more active, pain-free and drug-free lives.  Subsequently, Oska Pulse was named “best in show” by top golf publications, including Golf Digest.

About Oska Wellness
Oska, Inc. is committed to developing health and wellness technology-driven products that assist individuals in living a more active, pain-free lifestyle. Oska Pulse utilizes patented eTec Pulse Technology that specifically optimizes Pulsed Electromagnetic Field (PEMF) therapeutic technology, similar to the PEMF therapies used in many clinical applications for accelerating the body’s ability to heal itself.

The science and technology behind Oska Pulse was engineered and developed by a team of respected scientists and researchers with more than 25 years of experience in engineering health and wellness technologies to treat pain. Oska Wellness, Inc. does not claim the product to diagnose, treat, cure or prevent any medical condition. The company is headquartered in Carlsbad, California and can be found online at www.oksawellness.com.

CONTACT:
Robin Carr, Oska, Inc.
415-971-3991
162247@email4pr.com

ADD COUPON CODE  “ORTHOSPINECO”  FOR  $55.00 OFF

READ MORE ABOUT OSKA HERE

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oska-wellness-teams-up-with-arizona-golf-association-to-promote-the-revolutionary-oska-pulse-300465961.html


Rotation_CollagenImplant_WEB.png

June 6, 2017 OrthoSpineNews

American Health Network today announced that Dr. Brian Badman is the first and only shoulder surgeon in Indiana to treat patients suffering from rotator cuff disease using the Rotation Medical Bioinductive Implant – a new technology that helps tendons heal through the induction of new tissue growth, potentially helping patients resume normal activities quicker than traditional treatment and reducing the likelihood of further degeneration or re-tears.

The minimally invasive system is designed as a new option for people suffering from rotator cuff tendon tears in the shoulder joint, which affect more than 4 million people annually in the U.S. and are the most common source of shoulder pain and disability.

“Rotator cuff injury is common, and many patients avoid surgery because they hear about painful, lengthy postoperative rehabilitation and time away from work,” said Dr. Brian Badman. “The Rotation Medical Bioinductive Implant, which is about the size of a postage stamp, is inserted through a small incision during a minimally invasive arthroscopic outpatient procedure. The Bioinductive Implant induces the formation of new tendinous tissue over the surface of the tendon, resulting in a thicker tendon. Depending on their stage of rotator cuff disease, the Bioinductive Implant can provide patients a range of potential benefits, including shorter rehabilitation, faster recovery, prevention or slowing of disease progression, healing of partial-thickness tears, and decreased risk of developing a subsequent tear.” Several prominent orthopedic shoulder surgeons across the country have helped pioneer this technology including Dr. Jeff Abrams at Princeton and Dr. Buddy Savoie at Tulane University.

Rotator cuff tears are most often caused by chronic wear and tear with degeneration of the tendon. Rotator cuff tears can also occur in people who repeatedly perform overhead motions in their jobs or sports. In fact, more than 50 percent of people over age 60 have symptoms related to rotator cuff partial to full tearing of the tendon. Because traditional treatments do not address the poor quality of the underlying tendon tissue, a significant number of these tendons often develop into larger, more painful and debilitating tears and/or re-tears due to continuing degeneration of the torn tendon. The Bioinductive Implant allows surgeons to intervene early and potentially prevent disease progression by augmenting and healing the tendon before the injury worsens.

The Bioinductive Implant, manufactured by Rotation Medical, is suitable for most rotator cuff disease, from small partial-thickness tears to massive full-thickness tears. The Bioinductive Implant is derived from bovine Achilles tendon and gradually absorbs within six months, leaving a layer of new tendon-like tissue to biologically augment the existing tendon. This treatment can be used for both previously treated and untreated patients. Introduced to the market in 2014, the technology has been used in thousands of rotator cuff procedures in the U.S.

For more information, please visit Indyshoulder.com or to schedule an appointment with Dr. Badman, please call 317-208-3866.

About Dr. Badman
Dr. Badman grew up in South Bend, Indiana. He completed his orthopedic residency training at the University of Florida-Gainesville in 2005 and finished a shoulder and elbow fellowship at the Florida Orthopedic Institute in Tampa in 2006. Dr. Badman joined American Health Network (AHN) in 2011 as the founding member of AHN’s Bone & Spine group. He has subspecialty interest in shoulder and elbow disorders, with specialty training in arthroscopic rotator cuff repair, shoulder instability, total shoulder arthroplasty, reverse shoulder arthroplasty and proximal humeral fracture fixation. He is a member of the American Shoulder and Elbow Society and is only the fourth person from Indiana to be inducted into this prestigious international group of shoulder specialists. Over the past several years, Dr. Badman has consistently been one of the busiest reconstructive shoulder surgeons in the state, performing more than 150 replacement surgeries per year (total and reverse) and over 250 arthroscopic rotator cuff repairs annually.

About American Health Network’s Bone & Spine Group
American Health Network’s bone & spine physicians deal with diagnosis and treatment of diseases and injuries of the musculo-skeletal system, which includes bones, joints, muscles, ligaments, and tendons. The group provides fully integrated state-of-the-art care from diagnosis and treatment to rehabilitation. For more information, visit http://www.indyboneandspine.com


download-1.jpeg

June 6, 2017 OrthoSpineNews

06 Jun 17

Kuros (SIX:KURN) today announced it has filed the submission package for MagnetOs Putty seeking 510(k) clearance from the US Food and Drug Administration (FDA) for use as an autograft extender in posterolateral spine. MagnetOs is a novel synthetic bone graft substitute designed to support bone healing in the implanted site in the body. MagnetOs Putty is a moldable putty formulation of MagnetOs Granules, which is already cleared for commercialization in the United States of America and the European Union.

Dr. Ivan Cohen-Tanugi, Chief Executive Officer of Kuros, commented: “This FDA filing is yet another important milestone for Kuros as it eventually expands our portfolio of commercial-stage products. A similar submission for MagnetOs Putty in the EU will be filed in the next months.” He continued: “MagnetOs features a unique surface science technology that supports local bone formation. To meet surgeons’ preferences, we are developing a comprehensive product line consisting of different formulations and applications of MagnetOs. Furthermore, we plan to extend the existing labels into additional indications.”

MagnetOs Putty advantage

According to Kuros estimates, there are over 3 million procedures worldwide each year that use a bone graft material or a substitute. Patient-own bone (autograft) is still considered the gold standard bone grafting material. However, harvesting healthy bone usually requires a separate surgical procedure with associated costs, risks and morbidity.  Therefore, an extender that can be used in combination with local autograft, without the need for a separate autograft harvest procedure, offers significant potential benefits. Animal testing demonstrates comparable rates of bone healing for MagnetOs when used as an extender with autograft compared to autograft alone in a rabbit posterolateral fusion model.


AAEAAQAAAAAAAAeFAAAAJGRkMTcxZDUwLWNlZGEtNDBlYS04MjA4LTE2MWI1NTE1OTA2NQ.jpg

June 5, 2017 OrthoSpineNews

CARLSBAD, Calif., May 17, 2017 /PRNewswire/ — Oska Wellness, a technology company committed to developing innovated consumer health and wellness products, is partnering with MyTPI to promote Oska Pulse, a breakthrough wearable electromagnetic field device that eases pain. MyTPI has the largest collection of golf-specific health, fitness and swing advice on the Internet.

“We’re excited to be working with MyTPI, sharing our mission for new ways to provide non-invasive, drug free pain management solutions,” said Greg Houlgate, CEO of Oska Wellness.  “We’ve heard from many golfers who have had to cut back on playing due to pain. But thanks to the use of Oska Pulse, golfers can play one more round, pain free. Oska Pulse is a smart, safe, easy-to-use, wearable health technology product designed to help reduce muscle stiffness, temporarily relieve minor pain, and increase mobility for people who have acute or chronic pain.”

During the PGA Merchandise Show in January, Oska Wellness unveiled the Oska Pulse — a small, portable, hands-free device that employs safe Pulsed Electromagnetic Field (PEMF) therapeutic technology, a longtime therapy used by medical practitioners to help people enjoy more active, pain-free and drug-free lives.  Subsequently, Oska Pulse was named “best in show” by several leading golf publications, including Golf Digest.

“I’ve used Oska Pulse and got great results with mobility and pain relief from this device,” said David Phillips, co-founder of TPI.  “Our partnership with Oska Wellness will allow us be able to promote Oska Pulse to our leadership team, our affiliates, and our athletes. I’m a total believer in this product and I look forward to recommending it to our community.”

Phillips also said there are several ways to use the device. “After a round of golf, if you feel lower back pain or perhaps you have some wrist tendonitis,” he said. “Or prior to play, if you feel a little tightness in the morning. Use Oska Pulse on your way to the course.”  Developed by the experts at the Titleist Performance Institute, MyTPI.com delivers advanced golf-specific information from experts on six continents and 62 countries.

About Oska Wellness
Oska, Inc. is committed to developing health and wellness technology-driven products that assist individuals in living a more active, pain-free lifestyle. Oska Pulse utilizes patented eTec Pulse Technology that specifically optimizes Pulsed Electromagnetic Field (PEMF) therapeutic technology, similar to the PEMF therapies used in many clinical applications for accelerating the body’s ability to heal itself.

The science and technology behind Oska Pulse was engineered and developed by a team of respected scientists and researchers with over 25 years of experience in engineering health and wellness technologies to treat pain. Oska Wellness, Inc. does not claim the product to diagnose, treat, cure or prevent any medical condition. The company is headquartered in Carlsbad, California and can be found online at www.oksawellness.com.

ADD COUPON CODE  “ORTHOSPINECO”  FOR  $55.00 OFF

READ MORE ABOUT OSKA HERE

CONTACT:

Robin Carr, Oska, Inc.
415-971-3991
160282@email4pr.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oska-wellness-teams-with-mytpi-to-promote-oska-pulse-300459069.html